Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 806 Shares

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 806 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the transaction, the insider now owns 112,221 shares in the company, valued at $5,538,106.35. The trade was a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Dennis Cho also recently made the following trade(s):

• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The shares were sold at an average price of $44.90, for a total transaction of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The shares were sold at an average price of $46.81, for a total transaction of $6,225.73.
• On Friday, December 6th, Dennis Cho sold 367 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total value of $19,340.90.
• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $72,336.00.

Twist Bioscience Trading Up 3.2 %

NASDAQ TWST opened at $53.66 on Thursday. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The stock has a 50-day simple moving average of $48.74 and a two-hundred day simple moving average of $46.27.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.75) earnings per share. On average, research analysts anticipate that Twist Bioscience Co. will post -2.27 earnings per share for the current year.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently bought and sold shares of TWST. AQR Capital Management LLC increased its stake in Twist Bioscience by 83.9% during the 2nd quarter. AQR Capital Management LLC now owns 61,428 shares of the company’s stock worth $3,027,000 after buying an additional 28,027 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Twist Bioscience by 3.7% during the second quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company’s stock worth $1,531,000 after buying an additional 1,104 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Twist Bioscience by 407.1% in the third quarter. SG Americas Securities LLC now owns 10,958 shares of the company’s stock valued at $495,000 after buying an additional 8,797 shares during the last quarter. CWM LLC lifted its stake in shares of Twist Bioscience by 141.9% in the third quarter. CWM LLC now owns 5,894 shares of the company’s stock worth $266,000 after buying an additional 3,457 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its position in Twist Bioscience by 30.1% during the third quarter. Exchange Traded Concepts LLC now owns 20,141 shares of the company’s stock worth $910,000 after acquiring an additional 4,661 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TWST shares. Wolfe Research initiated coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Robert W. Baird raised their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday. Barclays decreased their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. raised their target price on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.